Characteristics of SARS-CoV-2 and potential pharmacological treatment
In December 2019 in Wuhan, China the first cases of previously unknown, coronaviral infection-induced pneumonia have been reported. The new virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) was named after SARS-CoV due to their similarities and the disease caused by the pathogen is COVID-19 (Coronavirus Disease 2019). On 11 March 2020 WHO (World Health Organization) defined the rapidly increasing number of incidents of COVID-19 as a pandemic. In this review we will present recent information about the SARS-CoV-2 focusing on the origin, clinical picture, diagnostic methods, structure, replication cycle of SARS-CoV-2 and potential pharmaceutical measures against COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Postepy biochemii - 66(2020), 2 vom: 09. Mai, Seite 83-90 |
| Sprache: |
Polnisch |
|---|
| Weiterer Titel: |
Charakterystyka wirusa SARS-CoV-2 i potencjalne farmakologiczne sposoby leczenia |
|---|
| Beteiligte Personen: |
Pawlik, Leon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.07.2020 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.18388/pb.2020_321 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312766181 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312766181 | ||
| 003 | DE-627 | ||
| 005 | 20231225145123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||pol c | ||
| 024 | 7 | |a 10.18388/pb.2020_321 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM312766181 | ||
| 035 | |a (NLM)32700510 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Pawlik, Leon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics of SARS-CoV-2 and potential pharmacological treatment |
| 246 | 3 | 3 | |a Charakterystyka wirusa SARS-CoV-2 i potencjalne farmakologiczne sposoby leczenia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In December 2019 in Wuhan, China the first cases of previously unknown, coronaviral infection-induced pneumonia have been reported. The new virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) was named after SARS-CoV due to their similarities and the disease caused by the pathogen is COVID-19 (Coronavirus Disease 2019). On 11 March 2020 WHO (World Health Organization) defined the rapidly increasing number of incidents of COVID-19 as a pandemic. In this review we will present recent information about the SARS-CoV-2 focusing on the origin, clinical picture, diagnostic methods, structure, replication cycle of SARS-CoV-2 and potential pharmaceutical measures against COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Śpiołek, Emilian |e verfasserin |4 aut | |
| 700 | 1 | |a Fichna, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Tarasiuk, Aleksandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Postepy biochemii |d 1954 |g 66(2020), 2 vom: 09. Mai, Seite 83-90 |w (DE-627)NLM000034541 |x 0032-5422 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2020 |g number:2 |g day:09 |g month:05 |g pages:83-90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18388/pb.2020_321 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2020 |e 2 |b 09 |c 05 |h 83-90 | ||